Please assess the completion status of the following clinical trial:

Trial Title: ProStat Supplementation in Dialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* On hemodialysis~* Optimally dialyzed with a biocompatible membrane (URR \> 70% and/or delivered Kt/V \>1.2)~* Patient or next of kin able to sign consent form~* Average of Serum Albumin for the consecutive two months prior to inclusion \</= 3.7 g/dl and the serum albumin for the previous month is \< 3.7 mg/dl.~* Sub-optimal nutritional status identified by one of the four following criteria:~  1. Protein catabolic rate less than 1.0 g/kg/d on at least 2 occasions over the past 6 months~ 2. Progressive unintentional weight loss more than 2.5% of the initial or ideal body weight and/or patients who are less than 90% of Standard Body Weight~ 3. Subjective Global Assessment Score consistent with Moderate to Severe Malnutrition within the last month~ 4. Biochemical parameters of malnutrition defined by 1 of 2 of the following measurements (if available) over the consecutive two months prior to inclusion:~     1. Serum transferrin concentration less than 225 mg/dl~    2. Serum prealbumin concentration less than 32 mg/dl~* Patient is able to transfer with minimal or no assistance.~* Not taking a caloric nutritional supplement for the last 30 days (e.g. Nepro, ProStat, Boost,etc).~Exclusion Criteria:~* Active auto-immune, inflammatory or infectious disease~* Documented malignancy within the last 12 months~* Patients on unusual dietary restrictions~* Life-expectancy less than 6 months~* Inability to tolerate nutritional supplements~* Patient does not exceed the DEXA machine weight limit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): Patients are randomly assigned to receive either Active Comparator (ProStat 64) or placebo for the first 3 months. At the end of this, all patients receive open label ProStat64.
- B (Type: PLACEBO_COMPARATOR): Patients are randomly assigned to Placebo Comparator or Active Comparator (ProStat 64). At the end of 3 months, all patients receive active ProStat 64

Based on this trial design, predict the completion outcome and termination type (if applicable).